GHP Q4 2019

26 GHP / Q4 2019 , As the second cohort of [email protected] Babraham start up competition winners begin their five-month programme, the Babraham Research Campus has confirmed a further injec- tion of financial and mentoring support for the initiative from new sponsors LifeArc. The additional funding will bolster the ability of the Babraham Research Cam- pus to drive innovation in early science within the Cambridge life science cluster. This year’s [email protected] ham competition awarded five ventures a cash prize of £10,000 each and access to laboratory and office facilities at the Babra- ham Research Campus. The 2019 cohort who were chosen to be on the programme, which was extended this year from three to five months are: • CC Bio • MicrofluidX • Reflection Therapeutics • ShiftBioscience • TropoFour Therapeutics The start-ups will also benefit from an in-depth programme of [email protected] Attracts Additional Sponsorship To Boost Innovation LifeArc joins AstraZeneca in providing funding towards the continued development of the BabrahamResearch Campus’ [email protected] initiative, which aims to nurture the development of early-stage science concepts and new life science companies. support, led by an elite group of academic and commercial life science experts. Derek Jones, CEO, Babraham Bioscience Technologies, which develops and manag- es the Babraham Research Campus commented: “The [email protected] initia- tive is different to many other programmes. As well as providing a non-dilutive cash prize, we also enable access to laboratory facilities to conduct the science, provide mentoring specific to their needs and deliver a wide-reach- ing programme to help challenge their thinking. In addition, we provide introductions to networks and investors that would not be available elsewhere. Our approach realises results and is attracting significant, heavy- weight support, of which LifeArc is a perfect example. The shared commitment of the Campus and LifeArc to support and bring on the next generation of scientists and talent within the life scienc- es sector is a great fit for both organisations.” LifeArc is already involved in activities at the Babraham Re- search Campus via agreements with Kymab and Cancer Re- search UK. Taking an active role in [email protected] will en- able the charity to become more involved with activities on cam- pus and the wider Cambridge ecosystem. It will also offer a window on potential investment opportunities coming through the [email protected] pipeline, which could be targets for further investment from LifeArc. The sponsorship comes from LifeArc’s Seed Fund, which makes investments and provides expertise for early stage spin-out companies within the UK. The fund aims to bridge the gap on the journey of translating innova- tion and incubate small start-ups to a point where they could attract venture funding. David Holbrook, Head of Seed Funds, LifeArc said: “LifeArc’s focus is on translation; progress- ing and supporting work from early, lab-based findings through to a point where it can be further developed and used to transform patients’ lives. Recognising the Babraham Research Campus’ overall contribution to the wider cluster and the support this programme gives to young talent was a major factor in our deci- sion to become more involved.”

RkJQdWJsaXNoZXIy NTY1MjM3
http://angelcofund.co.uk/ https://carb-x.org/carb-x-news/carb-x-awards-oxford-drug-design-funding-to-develop-a-new-class-of-antibiotics-to-treat-drug-resistant-gram-negative-infections/). https://www.drjohn.org/global-plant-protein-market-to-reach-279-billion-value-by-2025/ https://www.oxforddrugdesign.com/